Abstract: The invention provides methods and compositions for treatment of pain, such as joint pain, using capsaicin in a procedure that attenuates transient burning sensation experienced by patients due to capsaicin administration. The methods desirably provide relief from joint pain, such as osteoarthritic knee joint pain, for an extended duration, such as at least about 3 months, 6 months, 9 months, or 1 year. To attenuate the adverse side effect of a transient burning sensation caused by capsaicin-induced neuronal excitation, the methods utilize a cooling article, such as a material wrap cooled via a circulating fluid, to reduce the temperature of tissue to be exposed to capsaicin to within a certain range for certain durations of time, optionally in combination with administering a local anesthetic agent, resulting in the substantial reduction or even elimination of transient burning sensation caused by capsaicin.
Type:
Grant
Filed:
June 4, 2021
Date of Patent:
January 21, 2025
Assignee:
Centrexion Therapeutics Corporation
Inventors:
James N. Campbell, Peter D. Hanson, Randall Stevens
Abstract: The invention relates to the technical field of gene treatment and nano targeted delivery, in particular to a siRNA delivery system compound as well as a preparation method and application thereof.
Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
Abstract: The present disclosure pertains to the field of biomedicine, and specifically relates to a method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and optionally a therapeutically effective amount of a tubulin inhibitor. The present disclosure further relates to a pharmaceutical composition or kit comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and optionally a tubulin inhibitor.
Type:
Grant
Filed:
July 30, 2019
Date of Patent:
January 7, 2025
Assignee:
Ascentage Pharma (Suzhou) Co., LTD.
Inventors:
Dajun Yang, Yifan Zhai, Douglas Dong Fang, Guangfeng Wang, Qiuqiong Tang, Wentao Pan, Jiao Ji
Abstract: A combination drug contains hypoxanthine and human immunoglobulin (HIg). HIg has a therapeutic effect on radiation injuries, and the combination of hypoxanthine and HIg can further enhance this therapeutic effect. The combination drug can be administered to patients undergoing radiotherapy and to those who accidentally have excessive irradiation.
Type:
Grant
Filed:
July 11, 2022
Date of Patent:
January 7, 2025
Assignees:
Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Shanghai RAAS Blood Products Co., Ltd.
Inventors:
Zongkui Wang, Ming Cui, Changqing Li, Jun Xu, Lu Cheng
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
Type:
Grant
Filed:
December 13, 2019
Date of Patent:
December 31, 2024
Assignee:
Array Biopharma Inc.
Inventors:
James F. Blake, David A. Moreno, Li Ren, Tony P. Tang, Shane M. Walls
Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
Type:
Grant
Filed:
March 28, 2022
Date of Patent:
December 10, 2024
Assignee:
Oncternal Therapeutics, Inc.
Inventors:
Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Type:
Grant
Filed:
January 20, 2021
Date of Patent:
November 12, 2024
Assignee:
Genentech, Inc.
Inventors:
Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
Abstract: Provided herein are oligonucleotides, cell penetrating peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
Type:
Grant
Filed:
October 17, 2018
Date of Patent:
November 12, 2024
Assignees:
Sarepta Therapeutics, Inc., Massachusetts Institute of Technology
Inventors:
Justin M. Wolfe, Colin M. Fadzen, Zi-Ning Choo, Rebecca L. Holden, Monica Yao, Gunnar J. Hanson, Bradley L. Pentelute
Abstract: Crystalline forms of Compound A: characterized by its X-ray powder diffraction diagram, solid-state 13C NMR spectrum, MIR spectrum and Raman spectrum and pharmaceutical compositions containing it.
Type:
Grant
Filed:
December 5, 2019
Date of Patent:
October 29, 2024
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Emilie De Baets, Julien Auvray, Michael Lynch, Nicolas Leblanc
Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.
Type:
Grant
Filed:
June 6, 2022
Date of Patent:
October 29, 2024
Assignee:
NOVALIQ GMBH
Inventors:
Dieter Scherer, Ralf Grillenberger, Frank Löscher, Hartmut Voss
Abstract: In one aspect, the present application relates to an aminothiol-conjugate of formula (I): wherein R1, R2, R3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).
Type:
Grant
Filed:
December 13, 2022
Date of Patent:
October 29, 2024
Assignee:
THE BURLINGTON HC RESEARCH GROUP, INC.
Inventors:
Dale M. Walker, Vernon E. Walker, Tsvetelina I. Lazarova, Steven W. Riesinger
Abstract: Photostabilizing compounds are provided. In particular, the photostabilizing compound may be heterocyclic or homocyclic. Topical compositions comprising these photostabilizing compounds are also provided. In particular, these topical compositions further comprise photoactive compounds. Methods for stabilizing photoactive compounds are also provided. These methods comprise mixing the photoactive compounds with the photostabilizing compounds.
Abstract: The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.
Type:
Grant
Filed:
September 20, 2019
Date of Patent:
September 17, 2024
Assignee:
Bionomics Limited
Inventors:
Hamish Toop, Rajinder Singh, Erin Smith, Dharam Paul, Patrick Bazzini, Jean-Marie Contreras, Christophe Morice, Florence Chery, Fabrice Garrido
Abstract: The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.
Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
September 10, 2024
Assignees:
Novartis AG, Katholieke Universiteit Leuven, Korea Research Institute of Chemical Technology
Inventors:
Johan Neyts, Daniel Poon, Keith Bruce Pfister, Young-Sik Jung, Soo Bong Han, Yashwardhan R. Malpani, Prashant Chakrasali, Sang-Ho Lee, Chong-Kyo Lee, Chonsaeng Kim, Jin Soo Shin, Hae Soo Kim
Abstract: The subject invention pertains to compositions and methods of coating objects using BOC-butenolide. The invention also relates to compositions and methods for enhancing the performance and longevity of the coated objects with BOC-butenolide, including inhibiting fouling often caused by marine organisms.
Type:
Grant
Filed:
March 18, 2022
Date of Patent:
September 10, 2024
Assignees:
The Hong Kong University of Science and Technology, Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou)
Inventors:
Peiyuan Qian, Ho Yin Chiang, Jinping Cheng
Abstract: Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
Abstract: Tetradentate platinum complexes of Formulas I and II suitable for phosphorescent or delayed fluorescent and phosphorescent emitters in display and lighting applications.
Type:
Grant
Filed:
December 3, 2020
Date of Patent:
September 3, 2024
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY